The Antidote: Inside the World of New Pharma
| Author | : | |
| Rating | : | 4.31 (764 Votes) |
| Asin | : | 1451655673 |
| Format Type | : | paperback |
| Number of Pages | : | 448 Pages |
| Publish Date | : | 2018-02-05 |
| Language | : | English |
DESCRIPTION:
Joshua Boger, founding scientist and president, along with a group of young scientists, set out in a garage to overtake the big drug companies. The author returns to Vertex to learn what it takes to succeed in science and business and sees that 22 years later and at about four times the anticipated cost, Vertex is now set to achieve Boger’s initial goals: “Make better drugs, faster. From Booklist Werth, author and journalist, offers this sequel to The Billion-Dollar Molecule (1994), on the founding of the pharmaceutical company Vertex. --Mary Whaley . Become Merck, only better.” Werth seeks to discover what Boger’s vision has become and considers if it is a road map toward “a new biological epoch.” We learn that “all progress in the pharmaceutical business is backbreaking, freighted with unknowns, and takes twice as long as you think it will.” Now Vertex has nearly 2,000 employ
At a time when America struggles to maintain its innovative edge, The Antidote is a powerful inside look at one of the most intriguing and important business stories of recent decades.. Werth described the company’s tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. In this timely and much praised book, Barry Werth draws upon inside reporting that spans more than two decades. It’s riskier and more rigorous at just about every stage than any other business, from the towering biological uncertainties inherent in its mission to treat disease; to the 30-to-1 failure rate in bringing out a successful medicine even after a molecule clears all th
His landmark first book, The Billion-Dollar Molecule, recounts the founding and early struggles of Vertex. . Barry Werth is an award-winning journalist and the acclaimed author of six books. He has taught journalism and nonfiction writing at Smith, Mount Holyoke, and Boston University. Werth’s articles have appeared in The New Yorker, The New York Times Magazine, and GQ, among others
Ashutosh S. Jogalekar said The tribulations and triumph of drug development. As a biomedical scientist I really enjoyed this book. It is the sequel to the author's previous volume "The Billion Dollar Molecule". Both books provide a fly-on-the-wall account of Vertex Pharmaceuticals, an innovative biopharmaceutical company that brought two breakthrough medicines - one for hepatitis C and the other for cystic fibrosis - to market two years ago. Both these drugs were the first of their kind and have given thousands of patients a new lease on life. From a broader perspective however, the author's goal is to shed . "The Vertex Story continues" according to Thomas J. Dougherty. Extremely interesting followup to his previous book (The Billion-Dollar Molecule: The Quest for the Perfect Drug) on the biotech company Vertex. Many of the characters from the prior book have either moved on to other ventures or moved up the corporate ladder. Werth traces the evolution of Vertex from a feisty startup focused on perfecting an immunological anti rejection compound for transplants to the more mature company with a different focus and portfolio that it has become over three decades. It also serves as a cautionary tale . Epic Journey of Scientists trying to save the world Clergyboy This book is amazing because I never thought a corporation can have so many souls dancing inside, let alone a Pharma company. I want to say that I exaggerated only a little to compare this book's story to the 10 year Trojan War.What really touched me are the stories of individuals. The Bogers who "bore the torch" in the early days of doing great science and exploring the frontiers, the successors who financed and commercialized the founders' vision, the Wall Street analysts wanting to milk the new Pharmas like they did with the old,